非小细胞肺癌的免疫放化疗:联合试验中影响生存获益因素的荟萃分析
该荟萃分析汇总2018至2022年发表的cCRT-ICB临床研究、共2196例非小细胞肺癌患者(99%为3期),用荟萃回归分析2年OS与ICB、CRT及患者和肿瘤因素的关系,并将既往放疗或放化疗生存模型扩展纳入ICB效应。结果显示ICB带来的2年OS总体增益为9.9%(95%CI 7.6%~12.2%;P=0.018),OS增益随计划ICB持续时间延长和肿瘤PDL-1≥1%而升高,3B/C期患者拟合OS增益更大。
要点
- ICB带来的2年OS总体增益为9.9%(95%CI 7.6%~12.2%;P=0.018)。
- OS增益与2年OS均随计划ICB持续时间延长而升高(P=0.008、0.002)。
- 3B/C期患者和肿瘤PDL-1≥1%者拟合OS增益更高。
核心结论
- ICB带来的2年OS拟合增益在3B/C期患者比例更高和肿瘤PDL-1≥1%患者更多的队列中更高。
- 在计划ICB持续时间为2年而非1年的单个队列中OS增益也显著更高,但OS增益与ICB于CRT期间还是之后开始无关。
研究设计与样本
- 汇总2018至2022年发表的cCRT-ICB临床研究数据,共治疗2196例非小细胞肺癌患者(99%为3期)。
- 采用荟萃回归分析2年OS与ICB、CRT、患者及肿瘤因素的关联,并将既往放疗或放化疗生存模型扩展纳入ICB效应后同时拟合cCRT-ICB数据与既往单纯放疗或放化疗数据。
- 统计显著性采用似然比检验判定。
主要发现
- ICB带来的2年OS总体增益为9.9%(95%CI 7.6%~12.2%;P=0.018)。
- OS增益与2年OS均随计划ICB持续时间延长而升高(P=0.008、0.002)。
- OS增益与2年OS均随肿瘤PDL-1≥1%而升高(P=0.034、0.023)。
- 3B/C期患者的拟合OS增益更大(P=0.021)。
- OS增益与肿瘤组织学、患者体能状态、放疗剂量、ICB药物类型(抗PDL-1 vs 抗PD-1)以及ICB与cCRT同步开始还是序贯开始无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adding immune checkpoint blockade (ICB) to concurrent chemoradiotherapy (cCRT) has improved overall survival (OS) for inoperable locally advanced non-small cell lung cancer. Trials of cCRT-ICB are heterogeneous for factors such as tumor stage and histology, programmed cell death ligand-1 (PDL-1) status, and cCRT-ICB schedules. We therefore aimed to determine the ICB contribution to survival across studies and identify factors associated with survival gain. METHODS AND MATERIALS: Data were collated from cCRT-ICB clinical studies published 2018 to 2022 that treated 2196 patients with non-small cell lung cancer (99% stage 3). Associations between 2-year OS and ICB, CRT, patient and tumor factors were investigated using metaregression. A published model of survival after radiation therapy (RT) or CRT was extended to include ICB effects. The model was fitted simultaneously to the cCRT-ICB data and data previously compiled for RT/CRT treatments alone. The net ICB contribution (OS gain) and its associations with factors were described by fitted values of ICB terms added to the model. Statistical significance was determined by likelihood-ratio testing. RESULTS: The gain in 2-year OS from ICB was 9.9% overall (95% CI, 7.6%, 12.2%; P = .018). Both OS gain and 2-year OS itself rose with increasing planned ICB duration (P = .008, .002, respectively) and with tumor PDL-1 ≥ 1% (P = .034, .023). Fitted OS gains were also greater for patients with stage 3B/C disease (P = .021). OS gain was not associated with tumor histology, patient performance status, radiation therapy dose, ICB drug type (anti-PDL-1 vs anti-programmed cell death-1), or whether ICB began concurrently with or after cCRT. CONCLUSIONS: Fitted gains in 2-year OS due to ICB were higher in cohorts with greater fractions of stage 3B/C patients and patients with tumor PDL-1 ≥ 1%. OS gain was also significantly higher in a single cohort with a planned ICB duration of 2 years rather than 1, but was not associated with whether ICB treatment began during versus after CRT.
引用
- Huang HT, Brand DH, Fenwick JD, et al. ImmunoChemoradiation for Non-Small Cell Lung Cancer: A Meta-Analysis of Factors Influencing Survival Benefit in Combination Trials. Int J Radiat Oncol Biol Phys. 2024. PMID: 38570169. doi:10.1016/j.ijrobp.2024.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。